Research Papers:

Knockdown of long non-coding RNA CCAT2 suppressed proliferation and migration of glioma cells

Hua Guo _, Qing Yang, Guowen Hu, Pei Zhang, Wei Kuang, Xingen Zhu and Lei Wu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:81806-81814. https://doi.org/10.18632/oncotarget.13242

Metrics: PDF 2046 views  |   HTML 2894 views  |   ?  


Hua Guo1,*, Guowen Hu1,*, Qing Yang2, Pei Zhang1, Wei Kuang1, Xingen Zhu1, Lei Wu1

1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

2Department of Respiratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

*These authors have contributed equally to this work

Correspondence to:

Lei Wu, email: [email protected]

Xingen Zhu, email: [email protected]

Keywords: qRT-PCR, quantitative real-time PCR; lncRNA, long non-coding RNA (lncRNAs); CCK-8, cell counting kit-8

Received: September 14, 2016     Accepted: October 14, 2016     Published: November 09, 2016


Long non-coding RNA colon cancer-associated transcript 2 (CCAT2) is commonly investigated in a number of cancers. However, little is known of its expression and biological function in glioma biology. In the current study, we used quantitative real-time PCR (qRT-PCR) to determine the expression of CCAT2 in glioma tissues. We found that expression of CCAT2 was up-regulated in glioma tissues and significantly correlated with the advanced tumor stage (III/IV). Functional assays in vitro and in vivo demonstrated that knockdown of CCAT2 could inhibit proliferation, cell cycle progression and migration of glioma cells. Further analysis indicated the effect of CCAT2 knockdown on glioma cell phenotype through inhibiting Wnt/β-catenin signal pathway activity. Thus, our study provides evidence that CCAT2 may function as a potential biomarker for glioma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13242